Literature DB >> 1594480

Chromogranin A immunoreactivity compared with argyrophilia, calcitonin immunoreactivity, and amyloid as tumour markers in the histopathological diagnosis of medullary (C-cell) thyroid carcinoma.

H R Harach1, E Wilander, L Grimelius, U Bergholm, P Westermark, S Falkmer.   

Abstract

Applying the WHO criteria for the histopathological diagnosis of medullary thyroid carcinoma (MTC)--as well as the criterion that a significant amount of argyrophil cells, amyloid deposits, or calcitonin (CT) immunoreactive cells shall be present--122 cases were identified from the files of the Swedish Cancer Registry. Both non-occult (n = 110) and "occult" (less than 1 cm in diameter) (n = 12) MTCs were included. Both primary tumours (n = 91) and metastatic lesions (n = 31) were investigated. The specimens available were all only conventionally formalin-fixed and paraffin-embedded. The presence of neoplastic cells immunoreactive with antisera against chromogranin A (Chr A) was compared with that of the other three MTC markers. Chr A immunoreactive cells were present in practically all the cases. Similar results were obtained when the argyrophil reaction alone and CT immunoreactivity alone were used as markers. When two of the three MTC markers were combined, it was found that virtually everyone of the 122 tumours could be identified as a MTC. In contrast, the presence of amyloid deposits was found to be a less constant MTC marker; whereas 94% of the primary tumours had amyloid deposits, they were present in only approximately 70% and 60% of the metastatic and "occult" tumours respectively. No differences in the staining reaction patterns were found between familial (n = 18) and the sporadic (n = 104) types of MTC.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1594480     DOI: 10.1016/s0344-0338(11)81167-2

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  9 in total

1.  Fatal sporadic medullary carcinoma of the thyroid.

Authors:  H Ruben Harach; Ulla Bergholm
Journal:  Endocr Pathol       Date:  1993-03       Impact factor: 3.943

Review 2.  The granin protein family: markers for neuroendocrine cells and tools for the diagnosis of neuroendocrine tumors.

Authors:  P Rosa; H H Gerdes
Journal:  J Endocrinol Invest       Date:  1994-03       Impact factor: 4.256

Review 3.  [Thyroid C cells and their pathology: Part 2: Medullary thyroid carcinoma].

Authors:  S Synoracki; S T Schmid; S Ting; K W Schmid
Journal:  Pathologe       Date:  2015-05       Impact factor: 1.011

4.  Relationship of CD15 immunoreactivity and prognosis in sporadic medullary thyroid carcinoma.

Authors:  N Neuhold; F Längle; M Gnant; U Hollenstein; B Niederle
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

5.  Secretogranin IV immunoreactivity in medullary thyroid carcinoma: an immunohistochemical study of 62 cases.

Authors:  N Neuhold; R Ullrich
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

Review 6.  [Thyroid tumors].

Authors:  K W Schmid; S-Y Sheu; R Görges; C Ensinger; M Tötsch
Journal:  Pathologe       Date:  2003-09       Impact factor: 1.011

7.  Medullary carcinoma of the thyroid with carcinoid-like features.

Authors:  H R Harach; U Bergholm
Journal:  J Clin Pathol       Date:  1993-02       Impact factor: 3.411

8.  Medullary thyroid carcinoma, follicular variant.

Authors:  Mehtap Cakir; Hasan Altunbas; Mustafa Kemal Balci; Umit Karayalcin; Gulten Karpuzoglu
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

9.  The Pathology of Medullary Carcinoma of the Thyroid: Review of the Literature and Personal Experience on 62 Cases.

Authors:  Mauro Papotti; Daniela Sambataro; Carla Pecchioni; Gianni Bussolati
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.